The 7 major lung adenocarcinoma markets reached a value of US$ 14.2 Billion in 2023. Looking forward, the publisher expects the 7MM to reach US$ 27.5 Billion by 2034, exhibiting a growth rate (CAGR) of 7.62% during 2023-2034.
The lung adenocarcinoma market has been comprehensively analyzed in this report titled "Lung Adenocarcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Lung adenocarcinoma refers to a type of non-small cell lung cancer that originates in the glandular cells lining the air sacs (alveoli) in the lungs. This disease usually tends to grow slowly, but over time it often spreads to other parts of the body, such as the lymph nodes, liver, bones, or brain. The symptoms of lung adenocarcinoma can vary from person to person, and some patients may not develop any indications in the early stages. However, as the tumor grows and spreads, individuals suffering from the illness may experience persistent coughing, fatigue, shortness of breath, chest pain, unexplained weight loss, coughing up blood, lack of appetite, hoarseness or voice changes, recurrent respiratory infections, etc. The diagnosis of this condition typically requires a combination of medical history evaluation, characteristic findings, and a physical examination. Several diagnostic techniques, such as X-rays, positron emission tomography scans, magnetic resonance imaging, etc., may be adopted to visualize the lungs and identify any abnormal growths or masses. In some cases, a tissue biopsy is also performed to confirm the diagnosis among patients.
The increasing incidence of smoking tobacco, including cigarettes, pipes, and cigars, which can damage the lung tissue and create an environment that promotes the growth of cancerous cells, is primarily driving the lung adenocarcinoma market. In addition to this, the rising cases of germline variations in genes that are involved in DNA repair mechanisms and tumor suppression are also creating a positive outlook for the market. Moreover, the widespread adoption of minimally invasive radiofrequency ablation technique, which uses thermal energy to destroy cancerous cells and causes less trauma to the surrounding healthy tissue as compared to open surgeries, is further bolstering the market growth. Apart from this, the inflating application of targeted therapies, like tyrosine kinase inhibitors, owing to their various associated advantages, such as improved efficacy, long-term disease control, increased treatment outcomes, etc., is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy, which aims to treat the ailment by modifying or replacing defective genetic material with functional ones, is expected to drive the lung adenocarcinoma market during the forecast period.
This report provides an exhaustive analysis of the lung adenocarcinoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for lung adenocarcinoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the lung adenocarcinoma market in any manner.
The lung adenocarcinoma market has been comprehensively analyzed in this report titled "Lung Adenocarcinoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Lung adenocarcinoma refers to a type of non-small cell lung cancer that originates in the glandular cells lining the air sacs (alveoli) in the lungs. This disease usually tends to grow slowly, but over time it often spreads to other parts of the body, such as the lymph nodes, liver, bones, or brain. The symptoms of lung adenocarcinoma can vary from person to person, and some patients may not develop any indications in the early stages. However, as the tumor grows and spreads, individuals suffering from the illness may experience persistent coughing, fatigue, shortness of breath, chest pain, unexplained weight loss, coughing up blood, lack of appetite, hoarseness or voice changes, recurrent respiratory infections, etc. The diagnosis of this condition typically requires a combination of medical history evaluation, characteristic findings, and a physical examination. Several diagnostic techniques, such as X-rays, positron emission tomography scans, magnetic resonance imaging, etc., may be adopted to visualize the lungs and identify any abnormal growths or masses. In some cases, a tissue biopsy is also performed to confirm the diagnosis among patients.
The increasing incidence of smoking tobacco, including cigarettes, pipes, and cigars, which can damage the lung tissue and create an environment that promotes the growth of cancerous cells, is primarily driving the lung adenocarcinoma market. In addition to this, the rising cases of germline variations in genes that are involved in DNA repair mechanisms and tumor suppression are also creating a positive outlook for the market. Moreover, the widespread adoption of minimally invasive radiofrequency ablation technique, which uses thermal energy to destroy cancerous cells and causes less trauma to the surrounding healthy tissue as compared to open surgeries, is further bolstering the market growth. Apart from this, the inflating application of targeted therapies, like tyrosine kinase inhibitors, owing to their various associated advantages, such as improved efficacy, long-term disease control, increased treatment outcomes, etc., is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy, which aims to treat the ailment by modifying or replacing defective genetic material with functional ones, is expected to drive the lung adenocarcinoma market during the forecast period.
This report provides an exhaustive analysis of the lung adenocarcinoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for lung adenocarcinoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the lung adenocarcinoma market in any manner.
Time Period of the Study
- Base Year: 2023
- Historical Period: 2018-2023
- Market Forecast: 2024-2034
Countries Covered
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, current, and future epidemiology scenario
- Historical, current, and future performance of the lung adenocarcinoma market
- Historical, current, and future performance of various therapeutic categories in the market
- Sales of various drugs across the lung adenocarcinoma market
Competitive Landscape:
This report also provides a detailed analysis of the current lung adenocarcinoma marketed drugs and late-stage pipeline drugs.In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
- How has the lung adenocarcinoma market performed so far and how will it perform in the coming years?
- What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
- What was the country-wise size of the lung adenocarcinoma market across the seven major markets in 2023 and what will it look like in 2034?
- What is the growth rate of the lung adenocarcinoma market across the seven major markets and what will be the expected growth over the next ten years?
- What are the key unmet needs in the market?
Epidemiology Insights
- What is the number of prevalent cases (2018-2034) of lung adenocarcinoma across the seven major markets?
- What is the number of prevalent cases (2018-2034) of lung adenocarcinoma by age across the seven major markets?
- What is the number of prevalent cases (2018-2034) of lung adenocarcinoma by gender across the seven major markets?
- How many patients are diagnosed (2018-2034) with lung adenocarcinoma across the seven major markets?
- What is the size of the lung adenocarcinoma patient pool (2018-2023) across the seven major markets?
- What would be the forecasted patient pool (2024-2034) across the seven major markets?
- What are the key factors driving the epidemiological trend of lung adenocarcinoma?
- What will be the growth rate of patients across the seven major markets?
Lung Adenocarcinoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
- What are the current marketed drugs and what are their market performance?
- What are the key pipeline drugs and how are they expected to perform in the coming years?
- How safe are the current marketed drugs and what are their efficacies?
- How safe are the late-stage pipeline drugs and what are their efficacies?
- What are the current treatment guidelines for lung adenocarcinoma drugs across the seven major markets?
- Who are the key companies in the market and what are their market shares?
- What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the lung adenocarcinoma market?
- What are the key regulatory events related to the lung adenocarcinoma market?
- What is the structure of clinical trial landscape by status related to the lung adenocarcinoma market?
- What is the structure of clinical trial landscape by phase related to the lung adenocarcinoma market?
- What is the structure of clinical trial landscape by route of administration related to the lung adenocarcinoma market?
Table of Contents
?1 Preface3 Executive Summary6 Patient Journey9 Lung Adenocarcinoma - Unmet Needs10 Lung Adenocarcinoma - Key Endpoints of Treatment13. Lung Adenocarcinoma - Attribute Analysis of Key Marketed and Pipeline Drugs16 Lung Adenocarcinoma - Recent Events and Inputs From Key Opinion Leaders18 Lung Adenocarcinoma Market - Strategic Recommendations19 Appendix
2 Scope and Methodology
4 Lung Adenocarcinoma - Introduction
5 Lung Adenocarcinoma - Disease Overview
7 Lung Adenocarcinoma - Epidemiology and Patient Population
8 Lung Adenocarcinoma - Treatment Algorithm, Guidelines, and Medical Practices
11 Lung Adenocarcinoma - Marketed Products
12 Lung Adenocarcinoma - Pipeline Drugs
14. Lung Adenocarcinoma - Clinical Trial Landscape
15 Lung Adenocarcinoma - Market Scenario
17 Lung Adenocarcinoma Market - SWOT Analysis
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 129 |
| Published | May 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 14.2 Billion |
| Forecasted Market Value ( USD | $ 27.5 Billion |
| Compound Annual Growth Rate | 6.2% |
| Regions Covered | Global |
